– USA, NV – Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors.
“It’s my pleasure to welcome Brittany to our Board of Directors at this important next stage in Spectrum’s evolution. As a seasoned executive in M&A and the life sciences sector, Brittany’s experience and leadership will make an immediate impact on our board,” said Board Chairman, William Ashton.
About Brittany K. Bradrick
Brittany Bradrick has served as CFO of Neurelis, Inc. since October 2021. Before joining Neurelis, Ms. Bradrick was COO and CFO at ViaCyte. She previously served in strategy and corporate development positions for 10 years at Insulet Corporation as VP, Strategy & Corporate Development, and at Abbott Diabetes Care as the Head of Global Business Development. Before these positions, Ms. Bradrick was an investment banker for the life sciences sector at Piper Jaffray, Credit Suisse, and Chase Securities for 10 years. Ms. Bradrick began her career as a Federal Reserve Bank Examiner.
“I am looking forward to joining Spectrum’s Board at a time when the company has two product candidates that are under FDA review and approaching potential commercialization,” said Brittany Bradrick. “I intend to add value and contribute to the company’s mission of developing and delivering innovative medicines for patients with cancer.”
Ms. Bradrick holds an MBA from the Johnson Graduate School of Management at Cornell University and a B.S. in Business Administration from the University of Missouri.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals, and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company shortly.
For more information: https://www.sppirx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.